Residency · Residency · Obstetrics Gynecology

Preconception Counseling and Optimization

Overview

Preconception care is a systematic approach to optimizing maternal health before pregnancy, with the goal of reducing the risk of adverse obstetric and neonatal outcomes. Ideally, this process begins at least three months before conception, though some interventions -- such as weight optimization and chronic disease control -- benefit from a longer lead time. Because up to 50% of pregnancies in the United States are unplanned, reproductive life planning should be woven into routine primary care for all individuals of reproductive age, not reserved solely for those actively trying to conceive.

Folic Acid and Micronutrient Supplementation

Folic Acid

All women of reproductive age should take 400 to 800 mcg of folic acid daily. For women with a prior neural tube defect (NTD)-affected pregnancy, the dose increases to 4 mg daily, starting at least one month before conception and continuing through 12 weeks of gestation. Folic acid supplementation at these levels reduces NTD risk by approximately 70%. Since 1998, the United States has mandated fortification of grain products with folic acid, which has contributed to an approximately 25% decline in NTD prevalence at the population level.

Other Key Micronutrients

Iron status should be assessed and supplemented in cases of deficiency. Vitamin D levels (25-OH vitamin D) should be checked and maintained above 30 ng/mL. Iodine supplementation at 150 mcg daily is recommended, and it is worth noting that many prenatal vitamins are iodine-deficient. Omega-3 fatty acids are supported by emerging evidence for their role in fetal neurodevelopment.

Medication Review and Teratogen Avoidance

A systematic review of all prescription, over-the-counter, and herbal medications is essential at the preconception visit. Several high-risk medications require substitution or discontinuation before pregnancy. ACE inhibitors and ARBs can cause renal dysgenesis and oligohydramnios and should be switched to labetalol, nifedipine, or methyldopa. Valproic acid carries significant risks for neural tube defects and neurodevelopmental effects, and should be replaced with lamotrigine or levetiracetam when possible. Warfarin causes embryopathy in the first trimester and should be transitioned to low-molecular-weight heparin. Isotretinoin produces severe craniofacial, cardiac, and CNS malformations and must be discontinued with an appropriate washout period. Methotrexate is embryotoxic and fetotoxic and should be stopped three months prior to conception. Statins are generally avoided, though the risk classification remains debated.

It is important to note that the FDA replaced the older pregnancy letter categories (A/B/C/D/X) with the Pregnancy and Lactation Labeling Rule (PLLR) in 2015, which provides more nuanced, narrative-based risk information rather than a single letter grade.

Chronic Disease Optimization

Diabetes

Glycemic control before conception is one of the most powerful levers for reducing congenital anomalies. The target A1C is below 6.5%, and ideally below 6.0%, before conception. Each 1% increase in periconception A1C correlates with a measurably increased risk of congenital anomalies, and an A1C above 10% is associated with anomaly rates of 20 to 25%. Patients with type 2 diabetes should generally switch from oral agents to insulin, while those with type 1 diabetes should have their insulin regimens optimized.

Hypertension

ACE inhibitors and ARBs must be discontinued and replaced with pregnancy-safe antihypertensives. An evaluation for end-organ damage -- including renal function testing and echocardiography in patients with longstanding hypertension -- should be performed. Low-dose aspirin (81 mg) beginning at 12 weeks of gestation is recommended for preeclampsia prevention in high-risk patients.

Thyroid Disease

TSH should be optimized to below 2.5 mIU/L before conception. Hypothyroid patients on levothyroxine will typically need a 25 to 30% dose increase during pregnancy. In patients with Graves disease, methimazole should be switched to propylthiouracil (PTU) in the first trimester because methimazole is associated with aplasia cutis and choanal atresia.

Epilepsy

The goal is to optimize seizure control on the fewest medications at the lowest effective doses. Valproic acid should be avoided if possible. High-dose folic acid (4 mg) is recommended for all women on antiepileptic drugs.

Psychiatric Disorders

Clinicians must weigh the risks of untreated maternal mental illness against potential medication risks. SSRIs are generally considered acceptable in pregnancy, though paroxetine carries a slightly higher signal for cardiac defects. Lithium is associated with Ebstein anomaly, though the absolute risk is lower than previously estimated, at roughly 1 in 1,000.

Genetic Carrier Screening

ACOG recommends offering carrier screening for cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies to all patients. Expanded carrier panels covering over 100 conditions are increasingly available, though they require counseling about detection rates, residual risk, and variants of uncertain significance. Ethnic-specific screening should also be considered: an Ashkenazi Jewish panel (including Tay-Sachs, Canavan, and familial dysautonomia), sickle cell disease screening in populations of African descent, and thalassemia screening in Mediterranean, Southeast Asian, and Middle Eastern populations. If both partners are carriers of the same autosomal recessive condition, referral for genetic counseling before conception is essential. Options to discuss include preimplantation genetic testing, prenatal diagnosis, and use of donor gametes.

Infectious Disease Screening

Rubella immunity should be confirmed, and non-immune patients should be vaccinated with MMR (a live vaccine, requiring avoidance of conception for four weeks). Varicella immunity should likewise be verified, with vaccination if non-immune (also a live vaccine with a four-week interval). Additional screening includes hepatitis B surface antigen, HIV, and syphilis (RPR/VDRL). Hepatitis C screening should be considered, especially in patients with risk factors. Influenza and Tdap vaccines should be up to date, with Tdap given during each pregnancy at 27 to 36 weeks. COVID-19 vaccination is recommended before or during pregnancy.

Lifestyle and Environmental Factors

Tobacco cessation is strongly advised, as smoking is associated with intrauterine growth restriction, placental abruption, preterm birth, and SIDS. Alcohol cessation is equally important, since no safe level of alcohol consumption has been established and fetal alcohol spectrum disorders are entirely preventable. Patients should be counseled on the risks of cannabis and recreational drugs, including the association between marijuana use and low birth weight. Caffeine intake should be limited to less than 200 mg per day.

Weight optimization is a key component of preconception care. A BMI of 18.5 to 24.9 is ideal at conception. Obesity (BMI of 30 or greater) increases the risk of gestational diabetes, preeclampsia, macrosomia, cesarean delivery, and neural tube defects. Patients with a BMI of 40 or greater may benefit from referral to weight management programs or consideration of bariatric surgery, with the recommendation to allow 12 to 18 months between bariatric surgery and conception.

Environmental exposures -- including lead, mercury (with guidance to limit high-mercury fish), pesticides, and radiation -- should be reviewed. Regular exercise, aiming for 150 minutes of moderate-intensity activity per week, is recommended.

Reproductive History Assessment

A thorough reproductive history informs risk stratification and guides preventive strategies. Prior pregnancy complications such as preeclampsia, preterm birth, gestational diabetes, and stillbirth should all be documented. Patients with recurrent pregnancy loss should have their workup initiated before the next conception. Those with a prior cesarean delivery should be counseled on VBAC candidacy versus repeat cesarean. A short interpregnancy interval of less than 18 months is associated with adverse outcomes, and adequate spacing should be recommended.

Social Determinants and Access

The preconception visit should include screening for intimate partner violence, housing instability, and food insecurity. Insurance coverage and prenatal care access should be assessed and established. Mental health screening using tools such as the PHQ-9 and GAD-7 is appropriate, as is substance use screening using the SBIRT approach.

<image> A comprehensive flowchart showing the preconception counseling algorithm. The flowchart begins with "Reproductive-age patient presenting for preconception visit" and branches into parallel pathways: medical history review, medication assessment, genetic screening, immunization status, lifestyle optimization, and social determinants screening. Each branch shows specific actions and decision points, such as "A1C > 6.5%? Optimize glycemic control before conception" and "Non-immune to rubella? Vaccinate and advise 4-week wait." The flowchart converges at "Patient optimized for conception" with a notation of ongoing monitoring. </image>

<image> A medical illustration depicting the timeline of preconception interventions. The horizontal axis shows months before conception (6 months to 0). Key interventions are plotted along the timeline: at 6 months -- weight optimization, chronic disease management, genetic carrier screening; at 3 months -- folic acid supplementation begins, medication switches, immunizations; at 1 month -- confirm rubella/varicella immunity, finalize medication adjustments; at conception -- optimized A1C, stable medication regimen, prenatal vitamin established. Color-coded bars show duration of each intervention. </image>

<image> An anatomical illustration showing the embryologic structures affected by common teratogens during the preconception and early pregnancy period. The image shows a developing embryo at weeks 3-8 with labeled structures (neural tube, heart, limbs, face). Arrows point from specific teratogens (valproic acid, isotretinoin, warfarin, alcohol) to the structures they affect, with the critical windows of vulnerability highlighted in red. A legend indicates the type of malformation associated with each exposure. </image>

Key Clinical Pearls

The most critical window for organogenesis is weeks 3 through 8 post-conception, often before a patient knows she is pregnant -- this is precisely why preconception care matters so much. The preconception counseling encounter should be thoroughly documented, as it serves as a medicolegal record of informed decision-making. A1C is the single most impactful modifiable factor for reducing congenital anomalies in diabetic patients. Clinicians should always ask about over-the-counter supplements and herbal remedies, as patients often do not volunteer this information. Expanded carrier screening panels are increasingly standard but require robust pre-test counseling about the possibility of uncertain findings. The preconception visit is also an opportunity to discuss reproductive life planning for patients who do not desire pregnancy, by offering effective contraception. Finally, the interpregnancy interval deserves attention, as intervals shorter than six months carry the highest risk.

References

• ACOG Committee Opinion No. 762: Prepregnancy Counseling (2019)
• ACOG Committee Opinion No. 691: Carrier Screening for Genetic Conditions (2017, reaffirmed 2020)
• ACOG Practice Bulletin No. 233: Pregestational Diabetes Mellitus (2021)
• CDC Recommendations: Folic Acid for Prevention of Neural Tube Defects (updated 2022)
• FDA Pregnancy and Lactation Labeling Rule (PLLR), 2015
• Johnson K et al. Recommendations to Improve Preconception Health and Health Care. MMWR. 2006;55(RR-6):1-23

Read this lecture as Markdown